Britain testing Britain

Long-acting injection beats Truvada pill in HIV prevention trial

GlaxoSmithKline said an injection every other month of its cabotegravir drug was shown to avert an HIV infection more effectively than Gilead's daily Truvada pill, potentially giving its ViiV unit a foothold in HIV prevention.

The drug trial involving men who have sex with men was stopped early by an independent monitoring board after cabotegravir was found to be 69 percent more effective than the current standard of care, Truvada, the British drugmaker said on Monday.

All news from

The website is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

Breaking news
Editorial: We need more from Fauci, not less
Florida Walmart Shopper Pulls Gun On Father And Young Child After Being Asked To Wear A Mask: Watch
Russia Begins Targeting LGBTQ+ People, Per Putin's Orders